Open AccessCutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report
Author(s) -
Rahul R Tambe,
Anupa R A Hinduja,
Suchithra Sunil,
A Varaiya,
Amol Joshi
Publication year - 2021
Publication title -
indian journal of critical care medicine/indian journal of critical care medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.317
H-Index - 30
eISSN - 1998-359X
pISSN - 0972-5229
DOI - 10.5005/jp-journals-10071-24026
Subject(s) - medicine , mucormycosis , voriconazole , dermatology , pneumonia , covid-19 , disease , pathology , infectious disease (medical specialty) , antifungal
Coronavirus disease-2019 (COVID-19)-associated mucormycosis is on the rise in the Indian subcontinent. We report a unique case of cutaneous mucormycosis in a case of newly diagnosed young diabetic patient with severe COVID-19 pneumonia with post-COVID lung fibrosis. Neither did he have any preceding trauma or wound, nor was there any evidence of any secondary dissemination. Cutaneous mucormycosis without evidence of either is unheard off. Possible risk factors in this case were multiple bacterial secondary infections with the use of higher antibiotics, use of voriconazole for possible aspergillosis, and steroid use.